PE20070999A1 - Emulsion de acido graso esencial intravenosa - Google Patents

Emulsion de acido graso esencial intravenosa

Info

Publication number
PE20070999A1
PE20070999A1 PE2006001563A PE2006001563A PE20070999A1 PE 20070999 A1 PE20070999 A1 PE 20070999A1 PE 2006001563 A PE2006001563 A PE 2006001563A PE 2006001563 A PE2006001563 A PE 2006001563A PE 20070999 A1 PE20070999 A1 PE 20070999A1
Authority
PE
Peru
Prior art keywords
fatty acid
omega
intravenous
essential fatty
acid emulsion
Prior art date
Application number
PE2006001563A
Other languages
English (en)
Inventor
Jonathan David Bortz
Saul R Levinson
Original Assignee
Drugtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugtech Corp filed Critical Drugtech Corp
Publication of PE20070999A1 publication Critical patent/PE20070999A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DE UNA CANTIDAD EFICAZ DE ACIDOS GRASOS ESENCIALES SELECCIONADOS DE ACIDOS OMEGA 3, ACIDOS GRASOS DE OMEGA 6, ESTERES DE ACIDOS GRASOS DE OMEGA 6, ENTRE OTROS. COMPRENDE ADEMAS VITAMINAS DEL GRUPO B, E, D, A, K, ESTATINAS, HIERRO, ERITROPOYETINA, ZINC, CALCIO, PTH, QUELANTES LIPIDOS PROTEINAS, ENTRE OTROS, ADECUADA PARA LA ADMINISTRACION INTRAVENOSA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE HIPERTENSION, SUPLEMENTO NUTRICIONAL, INMUNOMODULACION, ENFERMEDAD AGUDA, ARRITMIAS, ENTRE OTROS
PE2006001563A 2005-12-09 2006-12-06 Emulsion de acido graso esencial intravenosa PE20070999A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59756205P 2005-12-09 2005-12-09
US78113706P 2006-03-10 2006-03-10

Publications (1)

Publication Number Publication Date
PE20070999A1 true PE20070999A1 (es) 2007-09-28

Family

ID=38163407

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001563A PE20070999A1 (es) 2005-12-09 2006-12-06 Emulsion de acido graso esencial intravenosa

Country Status (11)

Country Link
US (1) US20070154498A1 (es)
EP (1) EP1957039A2 (es)
JP (1) JP2009518424A (es)
KR (1) KR20080073288A (es)
AR (1) AR058295A1 (es)
AU (1) AU2006324155A1 (es)
BR (1) BRPI0619598A2 (es)
CA (1) CA2625640A1 (es)
IL (1) IL190728A0 (es)
PE (1) PE20070999A1 (es)
WO (1) WO2007070307A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
IL199781A0 (en) 2009-07-09 2010-05-17 Yohai Zorea Heat resistant probiotic compositions and healthy food comprising them
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
WO2010118362A1 (en) * 2009-04-09 2010-10-14 The Regents Of The University Of Colorado, A Body Corporate Methods and compositions for inducing physiological hypertrophy
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
US20110200644A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Ester Emulsions
US20110206741A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation DHA Triglyceride Emulsions
CN102892412B (zh) 2010-03-12 2015-09-30 博格制药有限责任公司 辅酶Q10(CoQ10)的静脉内制剂及其使用方法
WO2011133841A2 (en) 2010-04-23 2011-10-27 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Intravenous omega-3 fatty acid compositions & method of use
CA2823194A1 (en) * 2010-12-27 2012-07-05 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
CA2838311A1 (en) * 2011-06-07 2012-12-13 SPAI Group Ltd. Compositions and methods for improving stability and extending shelf life of sensitive food additives and food products thereof
US10973763B2 (en) 2011-06-17 2021-04-13 Berg Llc Inhalable pharmaceutical compositions
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
MY189402A (en) * 2014-11-07 2022-02-09 Mathew Jolly Vadakkemuri Optimized nutrient fatty acid composition
CA3052324C (en) 2017-03-03 2020-11-03 Exerkine Corporation Multi-nutrient composition
JP6508754B2 (ja) * 2018-05-11 2019-05-08 地方独立行政法人北海道立総合研究機構 放流用サケ稚魚の感染症予防剤
US11894121B2 (en) 2021-08-06 2024-02-06 Reviv Global Ltd Prescriptive nutrition-based IV and IM infusion treatment formula creation systems and methods
US11600375B2 (en) 2021-07-30 2023-03-07 Reviv Global Ltd Genetically personalized food recommendation systems and methods

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
JPS59172416A (ja) * 1983-03-18 1984-09-29 Terumo Corp 脂肪輸液
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
US6403349B1 (en) * 1998-09-02 2002-06-11 Abbott Laboratories Elongase gene and uses thereof
US7063838B1 (en) * 1999-09-24 2006-06-20 Proteon Therapeutics Llc Methods for treating an artery or vein in a human subject
US20050182434A1 (en) * 2000-08-11 2005-08-18 National Research Council Of Canada Method and apparatus for performing intra-operative angiography
US6271228B1 (en) * 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
EP1279400A1 (en) * 2001-07-25 2003-01-29 Target Hit sa Modifying the fatty acid composition of cell membranes of organs and tissues
US7241307B2 (en) * 2001-12-31 2007-07-10 Medcool, Inc. Method and apparatus for managing temperature in a patient
WO2004093824A2 (en) * 2003-04-08 2004-11-04 Fairfield Clinical Trials, Llc Peri-operative and peri-procedure nutritional supplementation
US20040248915A1 (en) * 2003-04-25 2004-12-09 Jacques Jolivet Method for administration of troxacitabine
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
CA2545752C (en) * 2003-11-12 2013-03-26 Children's Medical Center Corporation Treatment and prevention of liver disease associated with parenteral nutrition (pn)
US20060009486A1 (en) * 2004-07-07 2006-01-12 Gm Pharmaceuticals Inc. Composition and method for treatment and prevention of coronary artery disease

Also Published As

Publication number Publication date
AR058295A1 (es) 2008-01-30
JP2009518424A (ja) 2009-05-07
IL190728A0 (en) 2008-11-03
WO2007070307A2 (en) 2007-06-21
AU2006324155A1 (en) 2007-06-21
EP1957039A2 (en) 2008-08-20
CA2625640A1 (en) 2007-06-21
BRPI0619598A2 (pt) 2011-10-11
US20070154498A1 (en) 2007-07-05
KR20080073288A (ko) 2008-08-08
WO2007070307A3 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
PE20070999A1 (es) Emulsion de acido graso esencial intravenosa
EA200701913A1 (ru) Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
MX2010006199A (es) Composicion nutricional enterica liquida basada en caseina micelar, densa en cuanto a proteina.
WO2005079853A3 (en) Soft gelatin capsule comprising omega-3 polyunsaturated fatty acid
BR112014016788A2 (pt) composições de ácidos graxos poli-insaturados ômega-3 em forma de ácido livre, enriquecidas com dpa
WO2007073178A3 (en) Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
IL160012A0 (en) Modifying the fatty acid composition of cell membranes of organs and tissues
TW200744463A (en) Nutritional supplement containing long-chain polyunsaturated fatty acids
EA200100895A1 (ru) Незаменимые жирные кислоты для предотвращения сердечно-сосудистых приступов
CO6231039A2 (es) Composiciones que comprenden anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
CA2613792A1 (en) Methods and compositions for the prevention and treatment of inflammatory disease
ES2255467T1 (es) Acidos grasos de cadena media, gliceridos y analogos como estimuladores de la eritropoyesis.
AR063304A1 (es) Nueva composicion para mejorar la calidad de la piel y proceso para preparar la misma
CL2011000090A1 (es) Compuestos derivados de ácido grasos sustituidos interrumpido por un grupo azufrado; composicion farmaceutica alimentaria; metodo de preparacion de estos; y su uso en el tratamiento de enfermedades metabólicas, cardiovasculares,entre otras.
EA200970374A1 (ru) Лечение антиаритмическими средствами и омега-3 жирными кислотами и их комбинированным продуктом
RU2010120706A (ru) Композиция липоевой кислоты в виде шариков
CO6710941A2 (es) Concentrado de omega 3
AR061622A1 (es) Esteres del acido docosahexaenoico(dha), en particular el docosahexaenoato de piridin-3-il-metilo, metodo de preparacion, composicion farmaceutica que los contiene y su utilizacion en el tratamiento y prevencion de enfermedades cardiovasculares
RU2008117138A (ru) Способы и композиции для улучшения когнитивной функции
RU2009148576A (ru) Экструдаты с улучшенной маскировкой вкуса
AR033029A1 (es) Metodos para recuperar acidos grasos
RS52735B (en) APPLICATION OF A COMBINATION CONTAINING L-CARNITINE OR ALKANOIL L-CARNITINE, OIL-SOLUBLE OIL-BENZOQUINON AND OMEGA-3-POLYESATURATED FATTY ACID FOR PREPARATION OF NUTRITION OR MEDICINAL PRODUCTS
ES2613580T3 (es) Procedimiento para la producción de ácido grasos (poli)insaturados utilizando microalgas
ES2027057T3 (es) Procedimiento para preparar 2-aza-4-(alcoxicarbonil)espiro(4,5)decan-3-onas.
BR0304463A (pt) Processos para a produção de ésteres de ácidos carboxìlicos insaturados, e para a produção de ácidos carboxìlicos insaturados

Legal Events

Date Code Title Description
FD Application declared void or lapsed